Children in the world's poorest countries to get free insulin

Novo NordiskNovo Nordisk has announced that it will provide diabetes care, including free insulin, to 10,000 children in some of the world's poorest countries. The five-year programme, called 'Changing the Future for Children with Diabetes', will begin in 2009 with an initial roll-out in Uganda, Tanzania, Guinea-Conakry and the Democratic Republic of Congo.

It is estimated that some 38,000 African children aged 0–14 have type 1 diabetes. Sick children are particularly vulnerable in poor countries. A child in sub-Saharan Africa diagnosed with type 1 diabetes has a life expectancy of less than one year. A child with the same condition in the developed world has the possibility to live a full life.

"The premature death of a child caused by lack of insulin is unacceptable, when a life-saving solution is available. We must work together across borders to keep these children from dying; this is why I welcome this new programme being launched by Novo Nordisk today," says Professor Jean Claude Mbanya, president-elect of the International Diabetes Federation (IDF).

The programme will be based on a hub-and-spoke concept (satellite centres around existing hospitals/clinics) aimed at building long-term solutions for improving availability, accessibility, affordability and quality of diabetes care for children with type 1 diabetes.

"As a diabetes care company we have an obligation to use our resources and expertise to help these children. This project will not only provide insulin free of charge to an extremely vulnerable group, it is also designed to build long-term solutions for insulin distribution and sustainable diabetes care for all people with diabetes in the world's poorest countries," says Lars Rebien Sørensen, president and chief executive officer of Novo Nordisk A/S.

To this end, the project’s aim is to collaborate with as many local partners as possible, including governments and diabetes associations, regional chapters of the International Diabetes Federation (IDF) and key opinion leaders. Efforts to improve the healthcare infrastructure of participating countries will also help the programme to survive after the project period ends.

"The World Diabetes Foundation is committed to funding capacity building, awareness creation and development of sustainable infrastructure within existing structures to improve the care for children with diabetes in developing countries. We will work with Novo Nordisk and other relevant stakeholders to achieve this objective," says Anil Kapur, managing director for the World Diabetes Foundation (WDF).

Novo Nordisk announced the 'Changing the Future for Children with Diabetes' programme in connection with the 60th anniversary of the United Nations Universal Declaration of Human Rights.

Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services. With headquarters in Denmark, Novo Nordisk employs approximately 26,550 employees in 80 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit www.novonordisk.com.

Most Popular Now

Fasenra (benralizumab) receives US FDA approval fo…

AstraZeneca and its global biologics research and development arm, MedImmune, announced that the US Food and Drug Administration (FDA) has approved Fasenra (benralizumab)...

Pfizer receives FDA approval for SUTENT® (sunitini…

Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration has approved a new indication expanding the use of SUTENT® (sunitinib malate) to include...

Alzheimer's disease might be a 'whole body' proble…

Alzheimer's disease, the leading cause of dementia, has long been assumed to originate in the brain. But research from the University of British Columbia and Chinese scie...

Cancer cells destroyed with dinosaur extinction me…

Cancer cells can be targeted and destroyed with the metal from the asteroid that caused the extinction of the dinosaurs, according to new research by an international col...

Novartis confirms leadership in multiple sclerosis…

Novartis today announced it will present 54 scientific abstracts from across its multiple sclerosis (MS) research portfolio at the 7th Joint European and Americas Committ...

Amgen and Novartis announce expanded collaboration…

Amgen (NASDAQ:AMGN) and Novartis announced an expanded collaboration with the Banner Alzheimer's Institute (BAI) to initiate a new trial - the Alzheimer's Prevention Init...

Transplanted hematopoietic stem cells reverse dama…

Researchers at University of California San Diego School of Medicine report that a single infusion of wildtype hematopoietic stem and progenitor cells (HSPCs) into a mous...

Novartis announces the planned acquisition of Adva…

Novartis announced today, that it has entered a memorandum of understanding with Advanced Accelerator Applications (AAA) under which Novartis intends to commence a tender...

New tissue-engineered blood vessel replacements on…

Researchers at the University of Minnesota have created a new lab-grown blood vessel replacement that is composed completely of biological materials, but surprisingly doe...

'Precision Medicine' may not always be so precise

Precision Medicine in oncology, where genetic testing is used to determine the best drugs to treat cancer patients, is not always so precise when applied to some of the w...

New US study reveals key reasons why millions of p…

Few of the more than 90 million Americans(1) with obesity are seeking and receiving long-term obesity care, according to new data from the Awareness, Care and Treatment I...

Efficacy and safety maintained in patients who swi…

Boehringer Ingelheim today announced one-year data from VOLTAIRE®-RA, a pivotal Phase III clinical trial comparing Cyltezo® (adalimumab-adbm) and reference product Humira...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]